Traws Pharma, Inc.
TRAW · NASDAQ
12/30/2025 | 6/30/2025 | 12/31/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$0 | -$0 | -$0 | -$0 |
| Revenue | – | $0 | $0 | $0 |
| % Growth | – | 4,694.7% | 1.8% | – |
| Gross Profit | – | $0 | $0 | $0 |
| % Margin | – | 100% | 96.5% | 100% |
| EBITDA | – | -$0 | -$0 | -$0 |
| % Margin | – | -91.3% | -14,864.9% | -9,300% |
| Net Income | – | -$0 | -$0 | -$0 |
| % Margin | – | -22.9% | -14,868.4% | -8,898.2% |
| EPS Diluted | – | -0.11 | -8.81 | -5.92 |
| % Growth | – | 98.8% | -48.8% | – |
| Operating Cash Flow | – | -$0 | -$0 | -$0 |
| Capital Expenditures | – | $0 | $0 | $0 |
| Free Cash Flow | – | -$0 | -$0 | -$0 |